Background Next‐day discharge (NDD) outcomes following uncomplicated self‐expanding transcatheter aortic valve replacement have not been studied. Here, we compare readmission rates and clinical outcomes in NDD versus non‐NDD transcatheter aortic valve replacement with Evolut. Methods and Results Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry patients (n=29 597) undergoing elective transcatheter aortic valve replacement with self‐expanding supra‐annular valves (Evolut R, PRO, and PRO+) from July 2019 to June 2021 were stratified by postprocedure length of stay: ≤1 day (NDD) versus >1 day (non‐NDD). Propensity score matching was used to compare risk adjusted 30‐day readmission rates and 1‐year outcomes in NDD versus non‐NDD, and multivariable regression to determine predictors of NDD and readmission. Between the first and last calendar quarter, the rate of NDD increased from 45.4% to 62.1% and median length of stay decreased from 2 days to 1. Propensity score matching produced relatively well‐matched NDD and non‐NDD cohorts (n=10 549 each). After matching, NDD was associated with lower 30‐day readmission rates (6.3% versus 8.4%; P